Evidence map›Paper›PMID 17549068›Full record

ReviewThe pharmacogenomics journal2008

The clinical role of genetic polymorphisms in drug-metabolizing enzymes.

D Tomalik-Scharte, A Lazar, U Fuhr, J Kirchheiner

Abstract readReview
PubMed Publisher
In one paragraph

Review in The pharmacogenomics journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025
    Review
  10. Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  11. Personalized Approach in Eradication ofAntibiotics (Basel, Switzerland) · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Optimizing proton pump inhibitors inWorld journal of gastroenterology · 2019
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

D Tomalik-ScharteDepartment of Pharmacology, Clinical Pharmacology, University of Cologne, Köln, Germany. dorota.tomalik-scharte@uk-koeln.de
A Lazar
U Fuhr
J Kirchheiner

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For most drug-metabolizing enzymes (DMEs), the functional consequences of genetic polymorphisms have been examined. Variants leading to reduced or increased enzymatic activity as compared to the wild-type alleles have been identified. This review tries to define potential fields in the therapy of major medical conditions where genotyping (or phenotyping) of genetically polymorphic DMEs might be beneficial for drug safety or therapeutic outcome. The possible application of genotyping is discussed for depression, cardiovascular diseases and thromboembolic disorders, gastric ulcer, malignant diseases and tuberculosis. Some drugs used for relief of these ailments are metabolized with participation of genetically polymorphic DMEs including CYP2D6, CYP2C9, CYP2C19, thiopurine-S-methyltransferase, dihydropyrimidine dehydrogenase, uridine diphosphate glucuronosyltransferase and N-acetyltransferase type 2. Current evidence suggests that taking genetically determined metabolic capacities of DMEs into account has the potential to improve individual risk/benefit relationship. However, more prospective studies with clinical endpoints are needed before the paradigm of 'personalized medicine' based on DME variants can be established.

Indexed as

Antidepressive AgentsAntineoplastic AgentsAntitubercular AgentsAnti-Ulcer AgentsCardiovascular AgentsEnzymesFibrinolytic AgentsHumansPharmaceutical PreparationsPolymorphism, GeneticThromboembolismAntidepressive AgentsAntineoplastic AgentsAntitubercular AgentsAnti-Ulcer AgentsCardiovascular AgentsEnzymesFibrinolytic AgentsPharmaceutical Preparations

Identifiers

PMID17549068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.